Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Start Date24 Jun 2024

Sponsor / Collaborator

Novo Nordisk A/S

NCT06409130 / RecruitingPhase 2

Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or "dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

Start Date20 May 2024

Sponsor / Collaborator

Novo Nordisk A/S

NCT06403761 / RecruitingPhase 1

Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes

This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.

Start Date06 May 2024

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with CagriSema

100 Translational Medicine associated with CagriSema

100 Patents (Medical) associated with CagriSema

1,256

Literatures (Medical) associated with CagriSema

22 Jan 2024·Expert opinion on pharmacotherapy

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Review

Author: Mondoh, Alvin ; Le Roux, Carel

INTRODUCTION:

Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.

AREAS COVERED:

Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.

EXPERT OPINION:

The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.

International journal of obesity (2005)

What is the pipeline for future medications for obesity?

Review

Author: Melson, Eka ; Papamargaritis, Dimitris ; Ashraf, Uzma ; Davies, Melanie J

Abstract:

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.

Hepatology research : the official journal of the Japan Society of Hepatology

Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study

Article

Author: Lee, Yun Bin ; Shin, Hyunjae ; Yoon, Jung-Hwan ; Park, Youngsu ; Kim, Yoon Jun ; Sinn, Dong Hyun ; Ko, Yunmi ; Cho, Eun Ju ; Song, Byeong Geun ; Kim, Seung Up ; Lee, Jeong-Hoon ; Park, Jeayeon ; Yu, Su Jong ; Hur, Moon Haeng

Abstract:

Aim:

Antiviral treatment reduces the risk of developing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. However, there is a lack of high‐quality evidence regarding the preventive effects of tenofovir alafenamide (TAF) on HCC. We evaluated the impact of TAF use after curative treatment on HCC recurrence.

Methods:

Patients who underwent surgery or radiofrequency ablation as a curative treatment for HCC were selected. Those patients who continued antiviral treatment with nucleos(t)ide analogs (NAs; entecavir [ETV] or tenofovir disoproxil fumarate [TDF]) or switched to TAF were included. The primary outcome was HCC recurrence, and the time‐varying effect of NA use on HCC recurrence was analyzed using various statistical methods.

Results:

Among 2794 consecutive patients with chronic hepatitis B who received curative treatment for HCC, 199 subsequently switched from ETV or TDF to TAF. After a median of 3.0 years, 1303 patients (46.6%) experienced HCC recurrence. After propensity score matching (ratio 1:10), switching to TAF was not associated with an increased HCC recurrence (HR 1.00, 95% CI 0.68–1.47; p = 1.00) by time‐varying Cox analysis. Switching to TAF was not associated with HCC recurrence in subgroups of NA (HR 1.06, 95% CI 0.67–1.67; p = 0.81 for TDF, and HR 1.09, 95% CI 0.51–2.33; p = 0.82 for ETV). Kaplan–Meier analysis showed comparable HCC recurrence‐free survival between patients who switched to TAF and those who continued with their NA (p = 0.08). Time‐varying Cox analyses in various subgroups confirmed the primary findings.

Conclusions:

TAF is as effective as TDF and ETV in preventing HCC recurrence after curative treatment.

News (Medical) associated with CagriSema

18 Jun 2024

·www.novonordisk.com

Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association

FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes 1 SELECT cardiovascular outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity and established cardiovascular disease, without diabetes 2 STEP HFpEF trial programme data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity-related heart failure with preserved ejection fraction (HFpEF), with and without diabetes 3 ,4 Bagsværd, Denmark, 18 June 2024 – Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84 th Scientific Sessions of the American Diabetes Association (ADA). The conference will be held in-person and virtually from 21–24 June 2024 in Orlando, US. Additional data from three landmark trials with semaglutide will also be presented in dedicated scientific sessions. The trials assess additional potential benefits of semaglutide, including evaluation of kidney and cardiovascular endpoints in people with type 2 diabetes and chronic kidney disease (FLOW, semaglutide 1.0 mg) and cardiovascular and glucose-related endpoints in people with obesity and CVD, with and without diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg). “We recognise that cardiometabolic conditions like cardiovascular disease, chronic kidney disease, obesity and type 2 diabetes are often interlinked and might occur in the same patient. We need to develop medicines that address multiple facets of the diseases,” said Stephen Gough, senior vice president and global chief medical officer at Novo Nordisk. “The broad data being presented this year at ADA reflect this goal. In particular, data from FLOW and SELECT look at ways to treat common comorbidities of diabetes and obesity, such as kidney disease and cardiovascular disease.” All abstracts will be published on the website of the journal Diabetes ® . Data from the scientific sessions will be made available after their presentation. Summary of presentations Scientific sessions The following data will be presented in the dedicated scientific sessions as a part of the scientific agenda of the congress: The first dedicated kidney outcome trial with a GLP1-RA once-weekly semaglutide – FLOW trial results (scientific session; 24 June, 13:30–15:00 EST) SELECT trial – New looks at glycemia, inflammation, and heart failure (scientific session; 22 June, 08:00–09:00 EST) The STEP-HFpEF and STEP-HFpEF-DM trials – Targeting obesity to treat heart failure (scientific session; 23 June, 16:30–18:00 EST) Poster and oral presentations The following abstracts were submitted by Novo Nordisk and are accepted for presentation at the congress: Diabetes Ozempic ® (once-weekly semaglutide 1.0 mg) Comparative effectiveness of semaglutide in T2D – year 2 results of a randomized pragmatic clinical trial (230-OR) Long-term effectiveness associated with maintenance doses of once-weekly semaglutide in US adults with poorly controlled T2D (766-P) Semaglutide in patients with peripheral arterial disease and type 2 diabetes: comorbidities and concomitant medications from the STRIDE trial (784-P) Real-world impact of once-weekly injectable semaglutide on weight, BMI and HbA 1c outcomes in type 2 diabetes: an observational study (PAUSE) (857-P) Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D) - An Observational Study (PAUSE) (1884-LB) Rybelsus ® (once-daily oral semaglutide) Evaluating the efficacy of oral semaglutide in Chinese patients with T2D by baseline characteristics: post hoc analysis of PIONEER 11 and 12 (752-P) Real-world impact of fasting on adherence to dosing instructions and efficacy of oral semaglutide during Ramadan in people with type 2 diabetes: O-SEMA-Fast sub-analysis (808-P) CagriSema CagriSema improves insulin sensitivity in diet-induced obese rats (763-P) Once-weekly insulin icodec Healthcare resource utilization and costs with timely vs delayed basal insulin initiation (816-P) Demographic, clinical, and treatment characteristics of patients with timely vs. delayed basal insulin initiation (817-P) No evidence of increased physical activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T1D: ONWARDS 6 (824-P) Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in individuals with T2D by kidney function: ONWARDS 1–5 (826-P) No evidence of increased physical activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T2D: ONWARDS 1-5 (830-P) Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive T2D: post hoc analysis of ONWARDS 5 (836-P) Impact of age on the efficacy and safety of once-weekly insulin icodec versus once-daily insulin in T2D (ONWARDS 1–5) (838-P) Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1–5 (840-P) Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in T2D by ethnicity and race: ONWARDS 1–5 (841-P) Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada (1046-P) Efficacy and safety outcomes with once-weekly insulin icodec versus once-daily insulin degludec in T1D according to glycemic variability: ONWARDS 6 post hoc analysis (1882-LB) Daily insulins Influence of the functionally selective insulin analog NNC-965 on cardiac structure and function versus insulin glargine (IGla) (822-P) Improved glycemic control in people with type 2 diabetes (T2D) initiating or switching to insulin degludec/insulin aspart (IDegAsp) in a real-world setting in China (publication only) General diabetes Persistence and adherence of once weekly GLP-1 receptor agonists in patients with type 2 diabetes and atherosclerotic cardiovascular disease in a real-world setting (740-P) Impact of newer GLP-1 RAs on HbA1c in US adults with type 2 diabetes: a population-level time-series analysis (774-P) Understanding attitudes about basal insulin: insights from a global survey of people with type 2 diabetes (833-P) The value of the guideline-recommended management of type 2 diabetes: A novel population-level system dynamics approach (1040-P) Prevalence of atherosclerotic cardiovascular diseases in adults with type 2 diabetes in Jordan: the PACT-MEA Study (1789-LB) In vivo chain-splitting of human insulin (2032-LB) Digital Health Improvement in time in range after smart insulin pen initiation in Austria (842-P) Multinational analysis of factors associated with missed bolus insulin injections using smart pen data (843-P) Obesity Wegovy ® (once-weekly semaglutide 2.4 mg) CONCRETE – characterization of patients receiving telemedicine and branded antiobesity medication for medical weight management: a retrospective analysis (1684-P) Clinical outcomes in patients with obesity or overweight treated with semaglutide 2.4 mg: a real-world retrospective cohort study in the United States (SCOPE 2) (1691-P) Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2 (1981-LB) General obesity Patient-centered weight management clinical decision support: a proof-of-concept study (1101-P) Prevalence, characteristics, and clinical burden among patients with overweight or obesity and established ASCVD in a US real world setting (1692-P) About Ozempic ® Once-weekly subcutaneous semaglutide is approved in 0.5 mg, 1.0 mg and 2.0 mg doses under the brand name Ozempic ® and indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease. About Rybelsus ® Oral semaglutide is administered once daily and is approved for use in three therapeutic doses, 3 mg, 7 mg and 14 mg under the brand name Rybelsus ® . It is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise. About Wegovy ® Once-weekly subcutaneous semaglutide 2.4 mg is approved under the brand name Wegovy ® and is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in adults and paediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information Media: Ambre James-Brown +45 3079 9289 abmo@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com Ida Melvold Gjøsund +45 3077 5649 idmg@novonordisk.com Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com _______________________ References 1. ClinicalTrials.gov. A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). Available at: https://clinicaltrials.gov/study/NCT03819153. Last accessed: June 2024. 2. ClinicalTrials.gov. Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT). Available athttps://clinicaltrials.gov/study/NCT03574597. Last accessed: June 2024. 3. ClinicalTrials.gov. Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (STEP-HFpEF). Available at: https://clinicaltrials.gov/study/NCT04788511. Last accessed: June 2024. 4. ClinicalTrials.gov. Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (STEP HFpEF DM). Available at: https://clinicaltrials.gov/study/ NCT04916470. Last accessed: June 2024. Attachment PR240618-ADA_Global Curtain raiser

Drug ApprovalClinical ResultClinical Study

09 May 2024

·firstwordpharma.com

Flagship's Metaphore lands $600M Novo deal to 'mimic' better obesity drugs

Novo Nordisk is doubling down on its quest for novel obesity medicines, inking a potentially lucrative deal with Flagship Pioneering start-up Metaphore Biotechnologies to develop up to two multitarget therapeutics using the biotech's MIMIC platform.The Danish drugmaker could shell out up to $600 million in upfront and milestone payments, plus royalties, spurring hopes that Metaphore's machine learning-powered molecular mimicry approach could unlock a new class of longer-acting, more potent medicines aimed at the GLP-1 receptor and related obesity pathways.'Molecular mimics'"Metaphore's platform aims to mimic the interactions between molecules with impressive accuracy by capturing their natural dynamics at the point of interface, potentially leading to therapeutics that require infrequent dosing," noted Uli Stilz, head of Novo Nordisk's Bio Innovation Hub. The approach systematically isolates pharmacophores – the essential features where a drug binds its target – and designs "molecular mimics" that are then enhanced with fine-tuned therapeutic properties like function, selectivity, and multi-targeting.The collaboration stems from Novo Nordisk's strategic partnership with Flagship Pioneering from 2022. It also marks the third tie-up under the alliance following deals with Cellarity and Omega Therapeutics announced earlier the year to develop new treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH).As part of the latest deal, the partners will work toward advancing the programmes through to preclinical development, after which Novo Nordisk could decide to move them into clinical testing.Future financing roundIn addition to the up to $600 million in upfront, development and commercial milestones, and potential royalties to be split with Pioneering Medicines, Flagship's in-house drug development unit, Novo Nordisk will also cover research costs and participate in a future financing round for Metaphore. The biotech, which launched in 2023 with $50 million from Flagship, told FirstWord it had no additional details about the financing round "to share at this time."With over 800 million adults globally living with obesity, the pharmaceutical industry has been actively seeking to develop new treatments that could challenge Novo Nordisk's pole position with Wegovy (semaglutide). For its part, the Danish drugmaker continues to innovate in the space as well, with an obesity pipeline that includes a once daily oral version of Wegovy, as well as CagriSema, a fixed-dose, once-weekly injection combining semaglutide with amylin analogue cagrilintide. Both those programmes are currently in Phase III.The company is also working on once-daily oral and once-weekly subcutaneous forms of amycretin, a long-acting co-agonist of GLP-1 and amylin.

Phase 3

15 Apr 2024

·www.biospace.com

4 Investigational Weight Loss Drugs That Could Change the Market

Pictured: Four medicines with different routes of administration/Nicole Bean for BioSpace. Weight-loss treatments have quickly emerged as one of the hottest areas for R&D in the pharmaceutical industry. The rapidly realized blockbuster sales of the leading drugs in the space, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, means there is a strong interest in the pipeline of follow-on and next-generation drugs. J.P. Morgan forecasts that the glucagon-like peptide-1 (GLP-1) market alone will exceed $100 billion in revenue by 2030, through the use of these medicines in diabetes and obesity. According to IQVIA, the number of clinical trials for obesity drugs in 2023 was up by 68% from 2022, with 124 drugs in active development—of these, 40% are agonists of either the GLP-1 or glucose-dependent insulinotropic peptide (GIP) receptor. “The focus continues to be mainly GLP-1-based therapies,” Graig Suvannavejh, senior biopharmaceuticals and biotechnology equity research analyst at Mizuho Americas, told BioSpace, adding that there is a significant interest in combination approaches, such as Eli Lilly’s ‘triple-G’ approach, which binds and activates the GIP, GLP-1 and glucagon receptors. Suvannavejh said the oral delivery of these medicines is also of significant interest, as it could lower the cost of current peptide treatments by enabling lower manufacturing costs. This would allow for a greater number of patients to receive these types of treatments, he said. Of the assets that are moving through the pipeline, BioSpace highlights four potentially market-changing treatments. Though the focus of the industry’s pipeline has been on injectable GIP/GLP-1 assets, the leading companies have recognized the need to also approach the development of medicines from a new angle. Novo Nordisk’s Cagrilintide and Semaglutide Novo Nordisk is exploring a once-weekly subcutaneous combination of semaglutide and a novel amylin analog, cagrilintide. The use of an amylin analog would differentiate the company’s treatment portfolio from the current pipeline dominated by GIP/GLP-1 assets. Novo has already set the combination treatment, known as CagriSema, head-to-head against Eli Lilly’s Zepbound in a Phase III trial. In Phase II, the combination demonstrated greater body weight reduction in overweight people with type II diabetes. Body weight reduction was 15.6% with CagriSema compared to 5.1% in the semaglutide-only group and 8.1% in the cagrilintide-only group. Eli Lilly’s Orforglipron Eli Lilly has various assets in Phase III trials for weight loss, including orforglipron, which is a GLP-1 receptor agonist that is delivered as a once-daily oral treatment. Leaders in this space are racing to be the first-to-market with an oral treatment. This could be significant in garnering market share due to the aforementioned manufacturing advantages and the fact that oral delivery is generally preferable to subcutaneous delivery. In Phase II trials, orforglipron achieved statistically significant dose-dependent body weight reductions for all doses tested, according to Lilly’s June 2023 announcement. Viking Therapeutics’ VK-2735 In February, Viking Therapeutics revealed positive clinical trial results for its obesity candidate, VK2735—a dual GLP-1/GIP agonist, similar to Lilly’s Zepbound. Phase II results showed that the drug was able to achieve up to 13.1% placebo-adjusted mean weight loss. Then, last month, Phase I results revealed that an oral formulation of the treatment led to reductions in mean body weight. There were very few gastrointestinal adverse events reported 28 days after receiving VK2735, which could be an important differentiator as these side effects are a chief complaint associated with GLP-1 medicines. “Viking is viewed as one of the companies at the forefront of working on an oral formulation,” Suvannavejh said. The company noted in its Phase I data announcement that it would explore “longer treatment windows and potentially higher doses” in Phase II. Suvannavejh said this is because tolerability of the treatment appeared to be “quite good.” Outside of Lilly and Novo Nordisk’s portfolios, VK2735 is one of the furthest along in clinical development, so these data could signal the approach of a third player on the market—whether that be Viking or a future suitor of the company, with Suvannavejh suggesting that the company could be an acquisition target in the future. Inversago Pharma’s INV-202 A lesser-known drug candidate but backed by Novo Nordisk’s financial firepower, the CB1 receptor blocker could be another angle of attack for weight loss therapies. In June 2023, two months before Novo Nordisk’s $1 billion buyout, Inversago posted Phase Ib results for INV-202, an oral treatment, which elicited an average weight loss of 7.7 pounds for those treated with the candidate over a 28-day period, compared to 1.2 pounds for placebo comparators. The treatment has been specifically designed to block CB1 receptors in peripheral tissues to avoid the adverse events previously associated with the targeting of this pathway. Suvannavejh said these four treatments could be positioned as “combination approaches, and in patients who do not respond to GLP-1 or cannot tolerate the side effects.” Ben Hargreaves is a freelance science journalist based in Tosse, France. Reach him on LinkedIn.

Clinical ResultPhase 1Phase 2Acquisition

100 Deals associated with CagriSema

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	AR	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	AU	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	BR	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	BG	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	CA	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	CO	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	HR	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	CZ	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	DK	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024
Diabetes Mellitus, Type 2	Phase 3	FI	Novo Nordisk Pharmaceuticals Pty Ltd.	20 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2023	Not Applicable	-	-	CagriSema	jdqsftraqy(thvidbnuog) = vlkcviryxl aovjrdjkxp (zxolnwgejw ) View more	Positive	03 Oct 2023
				Cagrisema	jdqsftraqy(thvidbnuog) = gtsmacjihx aovjrdjkxp (zxolnwgejw )
NAASO2022	Not Applicable	-	-	Vehicle control	ihemiajacm(jquqqhulwl) = rtpcusjetg jccwgrgtmw (zaoeuhqfvf ) View more	-	21 Nov 2022
				CagriSema	ihemiajacm(jquqqhulwl) = jdoahvmcly jccwgrgtmw (zaoeuhqfvf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CagriSema

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation